Immunomedics, Inc.

NASDAQ: IMMU
$87.86
+$0.00 (+0.0%)
Closing price October 23, 2020
Here are four biotech stocks for which the team of analysts at Jefferies, and analysts at other firms, see big upside potential from upcoming near-term drug study catalysts.
Immunomedics watched its shares make a massive gain on Friday after the company announced the termination of its licensing deal with Seattle Genetics.
The health care sector was in trouble over the past year, under fire from congressional hearings and politicians on the campaign trail. At first 2017 seemed like it could be different for this...
In the week of October 7, there were multiple analyst calls for stocks to buy that were trading under $10 per share, including Petrobras and Brocade Communications.
The late-summer doldrums are over and the markets are on the move again as we are now in the fourth quarter. But a few companies held the market back from pushing even higher.
The top analyst upgrades, downgrades and initiations seen on Thursday morning include American Express, Encana, Petrobras, Raytheon, Tesla and Walgreens.
Shares of Immunomedics dropped sharply on Wednesday after the company announced the pricing of its secondary offering.
Biotech companies that lost their way last week truly burned shareholders, whether it was due to ASCO, earnings or even unfavorable clinical trial updates.
Some call the ASCO annual meeting the "Super Bowl for biotechs" because of the significance it holds for so many companies.
The king of biotech and pharma events is about to take place. The 2016 annual meeting of the American Society of Clinical Oncology (ASCO) is set to run from June 3 to June 7 in Chicago.
the top analyst upgrades, downgrades and initiations seen on Friday morning include Activision Blizzard, Berkshire Hathaway, FireEye, Immunomedics, Square, SunPower, Weatherford International,...
Friday's top analyst upgrades, downgrades and initiations include Ambarella, GoPro, LinkedIn, Mattel, Marriott, Qualcomm and Symantec.
Source: Jon OggStocks were indicated higher on Wednesday ahead of the pending FOMC decision on interest rates. Tuesday’s rally was yet another instance where investors proved that they want to buy...
Source: ThinkstockBelgian pharmaceutical group UCB announced Tuesday morning that its phase 3 trial for lupus treatment epratuzumab failed to produce statistically significant results in both dosages...
24/7 Wall St. has taken a look at some of the major ASCO winners over the past week and how they have performed since before the ASCO news.